期刊文献+

Pharmacokinetics of Remifentanil in Chinese Patients Undergoing Elective Surgery 被引量:2

择期外科手术期间国人瑞芬太尼的药物动力学研究(英文)
下载PDF
导出
摘要 Aim To study the pharmacokinetics of remifentanil in Chinese aduh patients undergoing elective surgery and compare the results with the data already published. Methods The pharmacokinetics of remifentanil was determined in 10 aduh patients undergoing elective surgery. Remifentanil 5 - 6 μg·kg^-1 was administered within 1 min after the induction of anesthesia. One point five millilitre of arterial blood samples were collected at 0 (baseline), 1,2, 3, 5,7, 10, 15, 20, 25, 30, 45, 60, and 90 min after drug administration. Remifentanil concentration was assayed by HPLC/MS/MS. Resuits The concentration-time course of remifentanil was best described by a two-compartment model. Total clearance (CL = 2. 149 ± 0. 431 L·min^-1) of remifentanil was greater than the normal hepatic blood flow. The distribution half-life (t1/2α) [ 1.56 ± 0. 52 min (0.73 - 2.31 ) ] and the elimination half-life (t1/2β) [22.07 ± 10.30 min (9, 71 -36.07)] were similar with those in previous reports. Volume of distribution ( Vd = 65. 766 ± 29. 100 L) was about two times greater than that reported in previous studies of other ethnics. Conclusion In the present study, the volume of distribution is significantly greater than thai reported in previous studies of other ethnics, indicating that there are some differences in the pharmacokinetics of remifentanil among different ethnics. 目的 测定国人全身麻醉下瑞芬太尼的药物代谢动力学参数,并与既往国外文献进行比较。方法 择期手术成年患者10例,在全麻诱导后静脉单次注射瑞芬太尼5~6μg·kg^-1,随后在注射后O、1、2、3、5、7、10、15、20、25、30、45、60及90分钟抽取动脉血。采用液质联用测定法(HPLC/MS/MS)测定瑞芬太尼血药浓度。结果 瑞芬太尼血药浓度-时间曲线变化符合二房室模型。平均分布半衰期(t1/2α)为1.56min(0.73~2.31),消除半衰期(t1/2β)为22.07min(9.71~36.07),清除率为(CL)2.149L·min^-1(1.370~2.629),表观分布容积(Vd)为65.766L(23.069~108.379)。结论 国人瑞芬太尼的药代动力学参数中表观分布容积明显大于国外研究结果,提示不同种族群体问的药代动力学变化存在差异。
出处 《Journal of Chinese Pharmaceutical Sciences》 CAS 2006年第1期33-37,共5页 中国药学(英文版)
基金 NationalHigh-techResearchandDevelopmentProgramofChina(No.2003AAIZ3413)
关键词 REMIFENTANIL PHARMACOKINETICS ANESTHESIA CHROMATOGRAPHY spectrum analysis 瑞芬太尼 药代动力学 麻醉 高效液相分析 质谱
  • 相关文献

参考文献10

  • 1Egan TD,Huizinga B,Gupta SK,et al.Remifentanil pharmacokinetics in obeseversuslean patients[].Anes-thesilogy.1998
  • 2Egan TD.Remifentanil pharmacokinetics and pharmaco-dynamics:a preliminary appraisal[].Clin Pharmacoki-net.1995
  • 3Egan TD,Minto CF,Hermann DJ,et al.Remifentanil versusalfentanil:comparative pharmacokinetics and phar-macodynamics in healthy adult male volunteers[].Anesthesiology.1996
  • 4Egan TD,Kern SE,Muir KT,et al.Remifentanil by bo-lus injection:a safety,pharmacokinetic,pharmacodyna-mic,and age effect investigation in human volunteers[].British Journal of Anesthesiology.2004
  • 5Luis GM,Carl CH.The pharmacokinetics of remifentanil[].JClin Anesthesia.1996
  • 6Glass PSA,Hardman O,Kamiyama Y.et al.Preliminary pharmacokinetics and pharmacodynamics of an ultrashort-acting opoid:remifentanil(GI87084B)[].Anesthesia and Analgesia.1993
  • 7Michelsen LG,Holford Nicholas HG,Lu W,et al.Thepharmacokinetics of remifentanil in patients undergoing coronary artery bypass grafting with cardiopylmonary by-pass[].Anesthesia and Analgesia.2001
  • 8Selinger K,Lanzo C,Sekut A.Determination of remifen-tanil in human and dog blood by HPLC with UV detection[].JPharm Biomed Anal.1994
  • 9Westmoreland CL,Hoke JF,Sebel PS,et al.Pharmaco-kinetics of remifentanil(GI87084B)and its major metab-olite(GI90291)in patients undergoing elective inpatient surgery[].Anesthesiology.1993
  • 10Egan TD,Harry JM,Pierre F,et al.The pharmacokinet-ics of the new short-acting opioid remifentanil(GI87084B)in healthy adult male volunteers[].Anesthesiology.1993

同被引文献19

  • 1邢玉英,张加强,贾丽,张爱玉,刘华琴,高雁,邵晓敏.食管癌切除术病人不同靶浓度瑞芬太尼复合异丙酚靶控输注的麻醉效果[J].中华麻醉学杂志,2005,25(11):865-866. 被引量:22
  • 2满元元,姜雨鸽,徐龙河,张宏.全静脉麻醉和平衡麻醉对支撑喉镜声带手术应激反应影响的比较[J].中国临床药理学与治疗学,2006,11(5):497-500. 被引量:4
  • 3张兴安,赵高峰,吴群林,徐波,施冲,王捷,屠伟峰.异丙酚全麻下瑞芬太尼在手术患者的药代动力学[J].中国临床药理学杂志,2006,22(6):414-417. 被引量:13
  • 4Rosow C. Remifentanil: a unique opioid analgesics[J]. Anesthesiology. 1993,79 (5) : 875 - 876.
  • 5Elloitt P, O'Hare R, Bill KM, et al. Severe cardiovascular depression with remifentanil[J]. Anesth Analg, 2000, 91(1):58-61.
  • 6Joshi GP, Warner DS, Twersky RS, et al. A comparison of the remifentanil and fentanyl adverse effect profile in a multieenter phase IV study[J]. J Clin Anesth, 2002, 14 (7) :494 - 499.
  • 7Akselord S, Gordon D, Ubel FA, et al. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control [J].Science, 1981, 213(4504) :220 - 222.
  • 8Mallianl A, Pagani M, Lombarti F, et al. Cardiovascular neural regulation explored in the frequency domain [J]. Circulation, 1991,84(2) : 482 - 492.
  • 9Kaya D, Kavaca S, Bamteu I, et al. Hear rate variability in patients with essential hyperhidrosis: dynamic influence of sympathetic and parasympathetic maneuvers [J]. Ann Noninvasive Electrocardiol, 2005,10( 1 ) : 1 - 6.
  • 10Shinohara K, Aono H, Mnruh GK, et al. Suppressive effects of remifentanil on hemodynamics in baro-denervated rabbits[J]. Can J Anaesth, 2000,47(4):361 - 366.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部